Caribou Biosciences Inc Dossier - Source-backed chat

Caribou Biosciences Inc

CRBUNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.84

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.22Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $130.8M

Enterprise Value $104.6M

Shares Outstanding 99M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Caribou Biosciences is a high-potential, clinical-stage CRISPR genome-editing company advancing next-generation, off-the-shelf (allogeneic) CAR-T cell therapies. By utilizing its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) technology, Caribou achieves superior genomic editing precision and armors its cell therapies to prevent rapid immune rejection. This technology addresses the historical durability and efficacy limitations of allogeneic platforms. With FDA alignment secured for the pivotal ANTLER-3 Phase 3 trial of its lead candidate vispa-cel (formerly CB-010) in second-line large B-cell lymphoma (LBCL), and promising early clinical data for its anti-BCMA candidate CB-011 in multiple myeloma, Caribou is well-positioned to achieve major clinical milestones. Strategic restructuring and pipeline prioritization have extended its cash runway into the second half of 2027, mitigating near-term financing risks while the company prepares for pivotal trial execution.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$11.86

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0015%

Vispa-cel's long-term durability data fails to match autologous CAR-T benchmarks, or safety concerns (such as severe cytokine release syndrome or graft-versus-host disease) emerge during the ANTLER-3 trial. CB-011 expansion data disappoints, and the company is forced to raise capital at highly dilutive, depressed valuations as its cash runway approaches the 2027 limit.

Base CaseCentral scenario

$8.7560%

Caribou successfully initiates the pivotal ANTLER-3 trial for vispa-cel and presents encouraging long-term follow-up Phase 1 data. CB-011 dose expansion data in 2026 confirms high complete response rates and a manageable safety profile. The company secures non-dilutive funding or utilizes its ATM facility moderately to extend its runway, keeping development on track with Wall Street consensus expectations.

Bull CaseUpside scenario

$19.0025%

The pivotal ANTLER-3 trial for vispa-cel demonstrates superior efficacy and durability compared to standard-of-care regimens, leading to rapid FDA approval as a best-in-class off-the-shelf therapy. Simultaneously, CB-011 continues to show exceptional response rates (92% ORR) in expanded cohorts, prompting a lucrative global co-development partnership with a major pharmaceutical firm that fully funds the pipeline and eliminates dilution concerns.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary Cas12a chRDNA platform provides industry-leading genomic editing precision, reducing off-target edits.
FDA alignment achieved on the pivotal ANTLER-3 Phase 3 trial design for lead candidate vispa-cel in 2L LBCL.
CB-011 granted FDA RMAT designation based on a strong 92% overall response rate in initial clinical cohorts.
Cash runway extended into 2H 2027 following strategic workforce reductions and pipeline prioritization.

Key Investment Risks

Clinical-stage risk: Lead candidates may fail to demonstrate long-term durability or safety in larger patient cohorts.
Financing risk: The company is pre-revenue and will require substantial additional capital to fully fund its pivotal trials.
Intense competition from both established autologous CAR-T therapies and other allogeneic CRISPR platforms.

Thesis Invalidation Triggers

Failure to initiate or enroll patients in the pivotal ANTLER-3 trial within the projected timeline.
A significant drop in the overall response rate (ORR) or durability of response in the CB-011 expansion cohort.
Severe, unexpected adverse safety events leading to FDA clinical holds on lead programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.